SynthesisEuropean journal of clinical pharmacology2026
Efficacy and safety of intravenous ferric carboxymaltose versus oral iron in pregnant women with anemia: a systematic review and meta-analysis.
Synthesis in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIntravenous (IV) ferric carboxymaltose represents an alternative to oral iron that enables rapid iron repletion through a single infusion, demonstrating promising efficacy and safety across diverse clinical settings. This study aims to evaluate the efficacy and safety of IV ferric carboxymaltose compared with oral iron in managing pregnancy-related anemia. MATERIALS AND
methodsWe systematically searched four databases for randomized controlled trials (RCTs) and observational cohorts comparing IV ferric carboxymaltose with oral iron in pregnant women with anemia. Randomized controlled trials and observational cohorts comparing intravenous ferric carboxymaltose with oral iron in pregnant women with anemia were included. Random-effects meta-analyses were performed using mean differences (MDs) for continuous outcomes and risk ratios (RRs) for dichotomous outcomes, each with 95% confidence intervals (CIs).
resultsTwelve studies (Eight RCTs and four cohorts) were included. IV ferric carboxymaltose significantly improved Hb concentrations compared with oral iron (7 RCTs & 4 Cohorts; 6,495 patients; MD = + 0.91 g/dL; 95% CI 0.30-1.51; p = 0.0035) and increased serum ferritin (5 studies; 4,420 patients; MD = + 63.8 ng/mL; 95% CI 37.3-90.4; p < 0.001). The benefit of Hb was most evident at pre-delivery (8 studies; 1,575 patients; MD = 1.22 g/dL, 95% CI [0.55-1.89], p = 0.0003) but not in the postpartum period (4 Studies, 5,141 patients; MD = 0.74, 95% CI [ -0.50-1.98], p = 0.24). Safety analyses demonstrated lower risks of drug-related adverse events (3 studies; 471 patients; RR = 0.42, 95% CI [0.19-0.91], p = 0.02) and nausea ( 3 studies; 3,284 patients; RR = 0.27, 95% CI [0.09-0.75], p = 0.012) with IV ferric carboxymaltose.
conclusionsIntravenous ferric carboxymaltose appears more effective than oral iron in improving hematologic indices in pregnant women with anemia and shows a favorable tolerability profile, including fewer drug-related adverse events and nausea. However, the findings should be interpreted cautiously, given the substantial heterogeneity across studies.
Indexed as
Identifiers
42426275What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.